Sleep apnoea-insomnia.

C. Guilleminault

1974-10-31

Abstract:

What problem does this paper attempt to address?

Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study

Brandon T McDaniel,Victor Cornet,Jeanne Carroll,Lambros Chrones,Joseph Chudzik,Jeanette Cochran,Shion Guha,Debra F Lawrence,Maggie McCue,Sara Sarkey,Betty Lorenz,Jay Fawver

DOI: https://doi.org/10.1186/s12888-023-05439-8

IF: 4.144

2023-12-13

BMC Psychiatry

Abstract:Background: This study included evaluation of the effectiveness of vortioxetine, a treatment for adults with major depressive disorder (MDD), using patient-reported outcome measures (PROMs) in a real-world setting. Methods: This retrospective chart review analyzed the care experiences of adult patients with a diagnosis of MDD from Parkview Physicians Group - Mind-Body Medicine, Midwestern United States. Patients with a prescription for vortioxetine, an initial baseline visit, and ≥ 2 follow-up visits within 16 weeks from September 2014 to December 2018 were included. The primary outcome measure was effectiveness of vortioxetine on depression severity as assessed by change in Patient Health Questionnaire-9 (PHQ-9) scores ~ 12 weeks after initiation of vortioxetine. Secondary outcomes included changes in depression-related symptoms (i.e., sexual dysfunction, sleep disturbance, cognitive function, work/social function), clinical characteristics, response, remission, and medication persistence. Clinical narrative notes were also analyzed to examine sleep disturbance, sexual dysfunction, appetite, absenteeism, and presenteeism. All outcomes were examined at index (start of vortioxetine) and at ~ 12 weeks, and mean differences were analyzed using pairwise t tests. Results: A total of 1242 patients with MDD met inclusion criteria, and 63.9% of these patients had ≥ 3 psychiatric diagnoses and 65.9% were taking ≥ 3 medications. PHQ-9 mean scores decreased significantly from baseline to week 12 (14.15 ± 5.8 to 9.62 ± 6.03, respectively; p < 0.001). At week 12, the response and remission rates in all patients were 31.0% and 23.1%, respectively, and 67% continued vortioxetine treatment. Overall, results also showed significant improvements by week 12 in anxiety (p < 0.001), sexual dysfunction (p < 0.01), sleep disturbance (p < 0.01), cognitive function (p < 0.001), work/social functioning (p = 0.021), and appetite (p < 0.001). A significant decrease in presenteeism was observed at week 12 (p < 0.001); however, no significant change was observed in absenteeism (p = 0.466). Conclusions: Using PROMs, our study results suggest that adults with MDD prescribed vortioxetine showed improvement in depressive symptoms in the context of a real-world clinical practice setting. These patients had multiple comorbid psychiatric and physical diagnoses and multiple previous antidepressant treatments had failed.
A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD)

Chong Guan Ng,Aya Ahmed Abousheishaa,Sue Yin Low,Nor Zuraida Zainal,Kai Shin Thong,Azizul Bin Awaluddin,Tsui Huei Loo,Sapini Binti Yacob,Nik Ruzyanei Nik Jaafar,Nur Iwana Abdul Abdul Taib,Nurul Ain Binti Mohamad Kamal,Fuad Ismail,Wan Zamaniah Wi

DOI: https://doi.org/10.31557/APJCP.2023.24.8.2583

2023-08-01

Abstract:Objective: Vortioxetine is a monoaminergic drug with a novel multimodal mechanism of action. We investigated its efficacy on depressive symptoms, cognitive function, and quality of life among cancer patients. Methods: In this multicenter, open-label, single-arm, observational study, patients received flexible doses of Vortioxetine for a period of six months. All participants were assessed at baseline and scheduled for monitoring at weeks 2, 4, 8, 12, 16, 20, and 24. Depression severity was assessed using Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression (CGI) scale. The Perceived Deficiency Questionnaire (PDQ-5) assessed the perceived cognitive difficulties in concentration, executive functioning, and memory. The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC) was used to assess the patients' quality of life. Side effects of vortioxetine were monitored using the Antidepressant Side-Effect Checklist (ASEC). Results: Patients experienced a reduction in MADRS scores from 29.89 ± 5.997 at baseline to 11.59 ± 4.629 by Week 24. The PDQ-5 scores showed significant change from Week-4, whereas the EORTC role, emotional, and cognitive functioning scores showed a significant change from Week 2 onwards. CGI-Severity scores decreased from a baseline of 4.39 ± 0.746 to 2.41 ± 1.085 by Week 24. During the 24-Weeks of therapy, around three-quarters of the patients (73.3%) had one or more adverse events reported on the ASEC. The most frequently reported TEAEs were dry mouth, insomnia, somnolence, and headache, with more than a 30% incidence rate. Conclusion: Vortioxetine seems promising in the management of depression and enhancement of cognitive function and quality of life of cancer patients with Major Depressive Disorder.<br />.
The effectiveness of vortioxetine on neurobiochemical metabolites and cognitive of major depressive disorders patients: A 8-week follow-up study

Yiliang Zhang,Shunkai Lai,Jianzhao Zhang,Ying Wang,Hui Zhao,Jiali He,Dong Huang,Guanmao Chen,Zhangzhang Qi,Pan Chen,Shuya Yan,Xiaosi Huang,Xiaodan Lu,Shuming Zhong,Yanbin Jia

DOI: https://doi.org/10.1016/j.jad.2024.01.272

IF: 6.533

2024-02-12

Journal of Affective Disorders

Abstract:Objective Vortioxetine has been shown to improve cognitive performance in people with depression. This study will look at the changes in neurobiochemical metabolites that occur when vortioxetine improves cognitive performance in MDD patients, with the goal of determining the neuroimaging mechanism through which vortioxetine improves cognitive function. Methods 30 depressed patients and 30 demographically matched healthy controls (HC) underwent MCCB cognitive assessment and 1H-MRS. After 8 weeks of vortioxetine medication, MCCB and 1H-MRS tests were retested in the MDD group. Before and after therapy, changes in cognitive performance, NAA/Cr, and Cho/Cr were examined in the MDD group. Results Compared with the HC group, the MDD group had significant reduced in verbal learning, social cognition, and total cognition (all p < 0.05). And the MDD group had lower NAA/Cr in Right thalamus and Left PFC; the Cho/Cr in Right thalamus was lower than HC; the Cho/Cr in Left ACC had significantly increase (all p < 0.05). The MDD group showed significant improvements in the areas of verbal learning, attention/alertness, and total cognitive function before and after Vortioxetine treatment (all p < 0.05). The NAA/Cr ratio of the right PFC before and after treatment ( t = 2.338, p = 0.026) showed significant changes. Conclusions Vortioxetine can enhance not just the depression symptoms of MDD patients in the initial period, but also their verbal learning, social cognition, and general cognitive capacities after 8 weeks of treatment. Furthermore, vortioxetine has been shown to enhance cognitive function in MDD patients by altering NAA/Cr and Cho/Cr levels in the frontal-thalamic-ACC.

psychiatry,clinical neurology
A 12-Month, Retrospective, Observational Study

José María García-Alberca,Paz De La Guia,Esther Gris,Silvia Mendoza,María Lopez De La Rica,Miguel Ángel Barbancho,José Pablo Lara,Encarnación Blanco-Reina

DOI: https://doi.org/10.3390/jpm14090918

IF: 3.5083

2024-09-01

Journal of Personalized Medicine

Abstract:This study aimed to assess the effectiveness of vortioxetine for improving depressive symptoms, cognitive performance, daily and global functioning in patients with Alzheimer's disease (AD) and major depressive disorder (MDD) in real-world clinical practice. We retrospectively identified 46 AD patients who had received treatment for 12 months with vortioxetine. Drug effects were evaluated at baseline, 4, 8, and 12 months. The primary endpoint was change from baseline in the Hamilton Depression Rating Scale (HDRS) and in the Cornell Scale for Depression in Dementia (CSDD) to month 12. Cognitive and daily and global functioning changes were also evaluated. Significant baseline-to-endpoint improvement in depressive symptom severity was observed (p < 0.0001). At month 12, the least-square mean (standard error) change score from baseline was −10.48 (±0.42) on the HDRS and −9.04 (±0.62) on the CSDD. Significant improvements in cognitive performance were observed for the Rey Auditory Verbal Learning Test, the Symbol Digit Modalities Test, the Letter Fluency Test, the Category Fluency Test, and the Trail Making Test-A. Patients also experienced significant improvements in daily and global functioning. Vortioxetine was safe and well tolerated. Patients with AD and MDD receiving vortioxetine showed meaningful improvements in depressive symptoms, cognitive performance, and daily and global functioning over the 12-month treatment period.

medicine, general & internal,health care sciences & services
Clinicopathologic conference: bluish gingival nodule.

M. Agostini,A. Abrahão,M. Cabral,B. D. de Andrade,M. Romañach

DOI: https://doi.org/10.1016/j.oooo.2015.06.032

2015-11-01

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Abstract:
Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232.

E. Larsen,W. Salzer,M. Devidas,J. Nachman,E. Raetz,M. Loh,N. Heerema,A. Carroll,J. Gastier-Foster,M. Borowitz,B. Wood,C. Willman,N. Winick,S. Hunger,W. Carroll

DOI: https://doi.org/10.1200/JCO.2011.29.15_SUPPL.3

IF: 45.3

2011-06-20

Journal of Clinical Oncology

Abstract:3 The full, final text of this abstract will be available in Part II of the 2011 Annual Meeting Proceedings, distributed onsite at the Meeting on June 4, 2011, and as a supplement to the June 20, 2011, issue of Journal of Clinical Oncology.
The role of community pharmacists in prescribing medication for the treatment of head lice.

Z. Philips,D. Whynes,S. Parnham,R. Slack,S. Earwicker

DOI: https://doi.org/10.1093/PUBMED/23.2.114

2001-06-01

Journal of Public Health Medicine

Abstract:BACKGROUND The aim of the study was to discover whether the use of community pharmacy, rather than general practice, as the first port of call for suspected head lice infestation would represent an acceptable, effective and cost-reducing means of management in the community. METHODS A before-and-after study was carried out of a new system of care delivery. Between September and November 1997, pharmacists in Nottingham City West recorded details of all patients attending with prescriptions for head lice treatment or those purchasing over-the-counter medication. The new system of care delivery began in January 1998, during which, pharmacists were providing advice and treatment for head lice, in the absence of a referral from general practice. Changes in prescribing behaviour were assessed from Prescribing Analysis and Cost (PACT) data. Acceptability and subjective assessment of the scheme (patients and professionals) was gauged from questionnaires. RESULTS Referral patterns were altered drastically (away from general practice and towards self-referral) by the project, and the changes were apparent within the first month. This trend continued throughout and beyond the formal evaluation period. Cost analysis suggests that the community pharmacy scheme generates resource savings, largely driven by the lower cost of a pharmacy consultation, as opposed to a GP consultation. Questionnaire evidence suggests that both patients and health care professionals viewed the new arrangement as at least as acceptable as the old. CONCLUSION With respect to the original objective, the new delivery system appears to provide no evidence of ineffectiveness; evidence of acceptability on the part of the majority of patients and professionals; and evidence of improved cost-effectiveness.
How to Construct a Logic for Your Application

D. Gabbay

DOI: https://doi.org/10.1007/BFb0018989

1992-09-03

Abstract:
Screening and prevention trials step up minority recruitment.

T. Reynolds

DOI: https://doi.org/10.1093/JNCI/88.18.1265

1996-09-18

Journal of the National Cancer Institute

Abstract:lowed by a disclaimer that the FDA has classified the substance as having no proven therapeutic benefits. A subsequent paragraph states that the sole purpose of the site is for "dialogue, exploration, research, and education," but clicking on a link at the bottom of the page brings up an order form and price list: a pound of shark cartilage powder for $99.95. Some cancer misinformation gets filtered out by patients, as it did in the newsgroup discussion of Hulda Clark and the Zapper. One discussion participant posted a message that described Clark as a quack researcher. But this discussion then degenerated into a heated flurry of personal attacks and legal threats: "I can't believe what a JERK you are," wrote the pro-Clark debater. "QUACK lover!" wrote the antiClark debater.
Clinical Benefits, efficacy and tolerability of slowly titrated vortioxetine oral drops solution

A. Fagiolini,A. Cuomo,G. Barillà,M. Cattolico,D. Koukouna,E. Mariantoni,S. Pardossi,C. Pierini,M. Pinzi,G. Piumini

DOI: https://doi.org/10.1192/j.eurpsy.2024.1130

2024-08-30

European Psychiatry

Abstract:Introduction Vortioxetine is mainly prescribed as oral tablets, usually starting at 5-10 mg per day, and is well tolerated by most patients. However, some patients may experience side effects, the most common of which is nausea, which occurs in 20.9-31.2% of people treated with doses of 5-20 mg/day (Baldwin et al, J Psychopharmacol. 2016;30:242-52). In some countries, vortioxetine is also available as an oral solution (1 drop = 1 mg), which allows a very slow titration schedule that may improve tolerability. Objectives To evaluate whether vortioxetine oral drop solution, started with 1-2 drops (1-2 mg per day) and increased by 1-2 drops per day to 10-20 drops (10-20 mg), is associated with better tolerability and a lower risk of nausea than that observed with oral tablets started with 5-10 mg per day, while maintaining efficacy. To provide pilot data for the design of a multicentre, prospective study. Methods Retrospective, single-centre, observational study. Participants were 58 consecutive patients (mean age 45 + 17 years, 55.2% female) treated with vortioxetine for a depressive episode. Vortioxetine was initiated and titrated up to 1 drop (1 mg) per day in 58.6% of subjects, and initiated and titrated up to 2 drops in 41.4% of subjects. Tolerability was assessed at all visits. CGI and MADRAS scores were recorded at the following time points: T0-baseline, T1=week 1, T2=week 2, T3=week 4, T4=week 8). Comparisons were made using repeated measures ANOVA with Bonferroni correction. Results Nausea was reported by 8 subjects (13.8%) at T1, 4 subjects (6.9%) at T2, 1 subject at T3 (1.7%) and none at T4. Other adverse reactions (mainly dizziness, pruritus/itching, vomiting, diarrhoea, and xerostomia) were reported by a total of 6 subjects (10.3%) at T1, none at T2 and T3, and 1 subject (1.7%) at T4. The maximum dose administered was 20 mg in 75.9% of patients. No patients discontinued vortioxetine due to adverse events, but vortioxetine was discontinued prior to T4 (8 weeks of treatment) in 2 subjects due to lack of efficacy. The mean CGI at baseline was 4.3 ±0.8. The mean value decreased to 3.9±0.7 at week 1 and to 3.4±0.6, 2.7±0.6, 1.9±0.5 at weeks 2, 4 and 8, respectively. All differences were statistically significant (p<0.001) compared to baseline. Also from week 2, all scores were statistically significant compared to all previous assessments. The total MADRS score decreased from 28.3±4.6 at baseline to 24.9±4.2, 20.9±4, 16.3±3.6 and 10.9±3 at weeks 2, 4 and 8, respectively. A significant decrease in MADRS total score was observed at each time point (p<0.001) compared to baseline and previous assessments. Conclusions Slow titration with vortioxetine oral drop solution was associated with a very low percentage of patients reporting side effects in general, and nausea in particular, and with a relatively rapid improvement in depressive symptoms. Disclosure of Interest None Declared

psychiatry
Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial

Chayan K Manna,Rajeev Ranjan,Pankaj Kumar,Shamshad Ahmad,Santanu Nath

DOI: https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_160_23

Abstract:Background: Vortioxetine and venlafaxine are antidepressants which have shown established efficacy to treat major depressive disorder (MDD). There are no studies that compared them for their efficacy in cognitive symptoms of depression. The study aimed to compare the effect of vortioxetine and venlafaxine on the change in cognitive scores in adults with MDD. Methods: The present study was an open-label, active-controlled parallel design randomized clinical trial. After randomization, baseline clinical evaluations by Montgomery-Asberg Depression Rating Scale (MADRS) and Social and Occupational Functioning Assessment Scale (SOFAS) were done and coding (subset of WAIS-IV), WCST, TMT, Stroop test, PGI memory were used to assess cognition in 100 unmedicated MDD patients. They were reassessed after eight weeks of monotherapy with vortioxetine or venlafaxine. Results: Primary cognitive measure (coding score) was found to be significantly higher (Mean Difference = 0.680; 95% CI:.202 to 1.158; P = 0.006) in vortioxetine in comparison with venlafaxine. Stroop test scores (word score, color score, color-word score) were also found to be significantly higher with vortioxetine. In other cognitive measures (WCST scores: total trials, total errors score, total perseverative responses score, total perseverative errors scores; TMT-A and B scores), a significant decrease in scores with vortioxetine in comparison with venlafaxine were observed. A significant decrease in MADRS and increase in SOFAS scores were observed with vortioxetine in comparison with venlafaxine. Both the drugs alleviated the symptoms of depression but vortioxetine was better tolerated. Conclusion: Our study findings suggest that improvement in cognitive scores is significantly higher with vortioxetine than venlafaxine over the eight weeks of monotherapy. Clinical trial registration number: CTRI/2020/07/026819 (Registered with Clinical Trials Registry- India).
Efficacy of vortioxetine versus desvenlafaxine in the treatment of functional impairment in patients with major depressive disorder: Results from the multinational VIVRE study

Michael Cronquist Christensen,Iria Grande,Andreas Rieckmann,Pratap Chokka

DOI: https://doi.org/10.1017/s1092852924000610

2024-10-30

CNS Spectrums

Abstract:Background In VIVRE (NCT04448431), vortioxetine was associated with significantly higher rates of symptomatic and functional remission, better daily and social functioning, and greater treatment satisfaction than desvenlafaxine in patients with major depressive disorder (MDD) and partial response to selective serotonin reuptake inhibitor (SSRI) therapy. This analysis further explored the relative improvement in patient functioning with vortioxetine versus desvenlafaxine. Methods VIVRE was a randomized, double-blind study of vortioxetine (10 or 20 mg/day) versus desvenlafaxine (50 mg/day) in adults with MDD and partial response to initial SSRI monotherapy. Mean percentage changes from baseline to week 8 in Functioning Assessment Short Test (FAST) total and domain scores were analyzed by treatment group in the overall population and in working patients. Results In the overall population, the mean reduction in FAST total score from baseline after 8 weeks of treatment was 37.2% in vortioxetine-treated patients versus 31.8% in desvenlafaxine-treated patients (P = 0.04). Significantly greater improvements versus desvenlafaxine were seen in vortioxetine-treated patients for FAST autonomy, cognitive functioning, and interpersonal-relationships scores (all P < 0.05). In working patients, the mean reduction in FAST total score from baseline at week 8 was 38.7% versus 32.1% in the vortioxetine and desvenlafaxine groups, respectively (P = 0.04). Significant correlations were seen between absolute changes in patient functioning, and those in depression severity and health-related quality of life. Conclusion Vortioxetine was significantly better than desvenlafaxine in improving overall functioning as well as daily, social, and cognitive functioning in patients with MDD with inadequate response to prior SSRI therapy.

psychiatry,clinical neurology
Vortioxetine in the Treatment of Major Depressive Disorder Among Working Patients in Routine Clinical Practice: An Analysis of a Post-Marketing Surveillance Study in South Korea

Seok Woo Moon,Jee Wook Kim,Do Hoon Kim,Michael Adair,Daniel Åström,Elin Reines,Minah Lee,Gayoung Kim

DOI: https://doi.org/10.2147/ndt.s478804

IF: 2.989

2024-11-28

Neuropsychiatric Disease and Treatment

Abstract:Seok Woo Moon, 1 Jee Wook Kim, 2 Do Hoon Kim, 3, 4 Michael Adair, 5 Daniel Oudin Åström, 6 Elin Heldbo Reines, 5 Minah Lee, 7 Gayoung Kim 7 1 Department of Psychiatry and Research Institute of Medical Science, Konkuk University School of Medicine, Chungju, South Korea; 2 Department of Neuropsychiatry, Hallym University Dongtan Sacred Heart Hospital, Dongtan, Korea; 3 Department of Psychiatry, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea; 4 Mind-Neuromodulation Laboratory, College of Medicine, Hallym University, Chuncheon, Korea; 5 Department of MSC Vortioxetine & Established Products, H. Lundbeck A/S, Valby, Denmark; 6 Department of Real-World Evidence & Epidemiology, H. Lundbeck A/S, Valby, Denmark; 7 Department of RA&MA, Lundbeck Korea Co., Ltd., Seoul, Korea Correspondence: Seok Woo Moon, Department of Psychiatry and Research Institute of Medical Science, Konkuk University School of Medicine, 82 Gugwon-daero, Chungju-si, Chungcheongbuk-do, 27376, South Korea, Tel +82-10-3276-1641, Email Background: Patients with major depressive disorder (MDD) experience depressive symptoms such as anhedonia as well as cognitive dysfunction which can subsequently impair their work performance. Purpose: To assess the effectiveness and safety of vortioxetine in working patients with MDD in South Korea. Patients and Methods: This was a subgroup analysis of a prospective, multicenter, non-interventional, non-comparative post-marketing surveillance (PMS) study. Vortioxetine-naïve patients aged > 18 years who were administered with vortioxetine were followed for up to 24± 2 weeks. Working patients were defined as those who were working or studying full- (≥ 6 hours/day) or part-time (< 6 hours/day) at baseline. Effectiveness and adverse events (AEs), assessed by both clinician and patient-reported measured, were analyzed. Results: A total of 1082 working patients (mean age: 39.56 years) were included in the subgroup analysis. Clinically significant improvements in depressive symptoms, including anhedonia, were observed over the 24 weeks of follow-up, with mean scores for the total Montgomery-Asberg Depression Rating Scale (MADRS) and anhedonia subscale both significantly decreasing from baseline by mean±standard deviation (SD) of 9.73± 9.08 and 5.37± 5.24 points, respectively, at 24 weeks (both p< 0.001 vs baseline). The vast majority of patients (80.01%) treated with vortioxetine also showed improvements in mental health symptoms over the 24 weeks, measured using the Clinical Global Impression – Improvement (CGI-I) scores. Significant improvements in cognitive symptoms were also observed over the study period, measured by the Korean Version of the Perceived Deficits Questionnaire-Depression as well as Digit Symbol Substitution Test (all p< 0.0001 from baseline at Visits 2 and 3). Vortioxetine was well tolerated in working patients, with the respective rates of any AEs and serious AEs being 18.67% and 1.20%. Conclusion: Working patients treated with vortioxetine had improvements in their depressive symptoms (including anhedonia), cognitive function and performance. Vortioxetine was found to be well tolerated in this study. Keywords: major depressive disorder, non-interventional, post-marketing surveillance, South Korea, vortioxetine, work performance Major Depressive Disorder (MDD) is a common psychiatric disorder in adults, with approximately 5% of adults having experienced depression globally. 1 MDD is one of the leading causes of health burden among the working-age population worldwide. 2,3 In 2019, depressive disorders were the 6 th highest cause of burden, measured using disability-adjusted life years, among those aged 25–49 years. 2,3 In South Korea, the burden of MDD is also increasing; between 1990 and 2017, South Korea had the 3 rd highest increase in age-standardized incidence of MDD among 195 countries. 4 MDD is associated with cognitive symptoms that have detrimental impacts on work performance, such as reduced work productivity and increased sick leave. Such adverse work-related outcomes due to MDD could pose substantial economic burden personally and to society. A modelling study in South Korea reported that MDD was estimated to result in 11,740 excess deaths in people of working age when compared with those without MDD, which translated to 55,126 years of life lost due to MDD. 5 The same study estimated that 1,627,333 productivity-adjusted life years were lost in the MDD cohort compared with those without MDD, equating to loss of appr -Abstract Truncated-

psychiatry,clinical neurology
The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence

James Lomas,Alexis Llewellyn,Marta Soares,Mark Simmonds,Kath Wright,Alison Eastwood,Stephen Palmer

DOI: https://doi.org/10.1007/s40273-016-0417-9

2016-06-11

PharmacoEconomics

Abstract:The National Institute for Health and Care Excellence (NICE) invited the manufacturer of vortioxetine (Lundbeck) to submit clinical and cost-effectiveness evidence for vortioxetine for the treatment of major depressive episodes (MDEs), as part of the Institute’s Single Technology Appraisal (STA) process. The Centre for Reviews and Dissemination and Centre for Health Economics at the University of York were commissioned to act as the independent Evidence Review Group (ERG). This article provides a description of the company submission, the ERG review and the resulting NICE guidance TA367 issued in November 2015. The ERG critically reviewed the evidence presented in the manufacturer’s submission and identified areas requiring clarification, for which the manufacturer provided additional evidence. Two phase III randomised controlled trials for a second-line population involving vortioxetine were identified—REVIVE and TAK318. These two trials represent only 972 of over 7000 patients included in trials of vortioxetine. In REVIVE, there was a statistically significant difference in depression scores favouring vortioxetine compared with agomelatine [mean Montgomery–Åsberg Depression Rating Scale (MADRS) score difference of 2.16 points; 95 % confidence interval 0.81–3.51]. The ERG concluded that, based on all the evidence, rather than the substantially restricted subset of evidence originally considered by the manufacturer, vortioxetine is likely to be similar in efficacy to other analysed antidepressants [citalopram, sertraline, escitalopram and venlafaxine extended release (XR)], and may be more efficacious than agomelatine and inferior to duloxetine. The ERG concluded that vortioxetine may be more tolerable than other analysed antidepressants (sertraline, venlafaxine XR and bupropion), although the limited data prevent firm conclusions. The base-case incremental cost-effectiveness ratio (ICER) of vortioxetine reported by the manufacturer was £378 per quality-adjusted life-year (QALY) compared with venlafaxine. Given considerable concerns about the indirect treatment comparison undertaken by the manufacturer, the use of only a restrictive subset of the available evidence, and concerns regarding comparators and structural model assumptions, the ERG believes that this is not a valid estimate of the cost effectiveness of vortioxetine. Following corrections made to the model made by the ERG, the estimated cost effectiveness of vortioxetine was sensitive to the source of evidence used, in addition to whether certain comparators were excluded. The NICE thus asked the manufacturer to provide a revised economic model, which incorporated the broader evidence base and considered the cost effectiveness of vortioxetine as a third-line treatment. Assuming equal efficacy, vortioxetine was shown to be less costly and generate a higher QALY gain than relevant comparators at the third-line of treatment owing to its tolerability and adverse event profile. The NICE Appraisal Committee recommended vortioxetine as an option for treating MDEs in adults whose condition has responded inadequately to two antidepressants within the current episode.

pharmacology & pharmacy,health care sciences & services,health policy & services,economics
Effectiveness of Vortioxetine in Working Patients with Major Depressive Disorder in China: A Subgroup Analysis of the RELIEVE China Study

DOI: https://doi.org/10.2147/ndt.s460408

IF: 2.989

2024-06-08

Neuropsychiatric Disease and Treatment

Abstract:Gang Wang, 1, &ast Tianmei Si, 2, &ast Andreas Rieckmann, 3 Jingdong Ma, 4 Michael Cronquist Christensen 3 1 The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital & The Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, People's Republic of China; 2 Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, People's Republic of China; 3 Global Medical Affairs, H. Lundbeck A/S, Valby, Denmark; 4 Medical Affairs, Lundbeck China, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Michael Cronquist Christensen, Global Medical Affairs, H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark, Tel +45 3083 5168, Email Background: Major depressive disorder (MDD) causes significant functional impairments that impact on all aspects of patients' daily lives, including their ability to work, work productivity, and social life. Purpose: To assess the real-world effectiveness of the multimodal antidepressant vortioxetine in working patients with MDD in China. Patients and methods: RELIEVE China was an observational, prospective cohort study. Patients (aged ≥ 18 years) with MDD initiating treatment with vortioxetine in routine clinical practice settings were followed for 24 weeks. In this subgroup analysis, functioning was assessed using the Sheehan Disability Scale (SDS) in patients in full- or part-time work or education at baseline who remained on treatment at all follow-up visits (n=424). Depressive, cognitive, and anxiety symptoms were also assessed. For all endpoints, mean change from baseline at weeks 8 and 24 was analyzed using mixed models for repeated measures. Results: Clinically relevant and sustained improvements in patient functioning and measures of work productivity were observed over the 24 weeks of vortioxetine treatment. The adjusted mean (standard error) reduction in SDS total score from baseline was 5.4 (0.3) points at week 8 and 8.7 (0.3) points at week 24 (both P < 0.001 vs baseline). Significant improvements were observed across all SDS domains and in levels of absenteeism and presenteeism ( P < 0.001 vs baseline for all endpoints at both time points). Significant improvements in depressive, cognitive, and anxiety symptoms were also observed over the study period (all P < 0.001 vs baseline). The proportion of patients in remission (ie, 17-item Hamilton Depression Rating Scale score ≤ 7) after 24 weeks of vortioxetine treatment was 65.4%. Vortioxetine was well tolerated; nausea was the most common adverse event, reported by 18.6% of patients. Conclusion: These findings support the effectiveness and tolerability of vortioxetine in working patients with MDD receiving treatment in routine clinical practice settings in China. Keywords: China, cognitive symptoms, major depressive disorder, patient functioning, vortioxetine, work productivity Depression is a highly prevalent and debilitating condition that is estimated to affect approximately 280 million people worldwide, 1 including over 50 million people in China alone. 2 It is a leading cause of disability and a major contributor to the overall global burden of disease. 3,4 Depression is associated with functional impairments that have a detrimental impact on all aspects of patients' daily lives, including their ability to work and their productivity while at work. 5–7 As such, the economic impact of depression in the workplace is considerable. 6 Indeed, work-related costs have been shown to account for a major proportion of the overall economic burden of depression. 8 In 2016, the mean annual population-level cost of depression-associated absenteeism (ie, days lost from work) and presenteeism (ie, lower productivity while at work) in China was estimated to be US$20 billion, 80% of which was attributable to presenteeism. 6 Data from the landmark Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study have shown that individual symptoms differ in their impact on psychosocial functioning in patients with major depressive disorder (MDD), with sad mood, cognitive symptoms, fatigue, and loss of interest having the greatest impact. 9 Cognitive symptoms (eg, impairments in attention, memory, processing speed, and all aspects of executive functioning) are com -Abstract Truncated-

psychiatry,clinical neurology
Metabolic Effects of Antidepressants: Results of a Randomized Study's Interim Analysis

N Simple Santi,Sashi B Biswal,Birendra Narayan Naik,Jyoti Prakash Sahoo,Bhabagrahi Rath

DOI: https://doi.org/10.7759/cureus.42585

2023-07-27

Cureus

Abstract:Background and objectives: Individuals with major depressive disorder exhibit a dysregulated metabolic profile. There are few studies on how vilazodone, escitalopram, and vortioxetine alter metabolic parameters. Our study aimed to determine the change in plasma glucose, HbA1c, serum cholesterol, triglyceride, and creatinine at 12 weeks. Methods: An ongoing randomized, open-label, three-arm study's interim analysis is portrayed here. The participants were assessed at baseline, 4, 8, and 12 weeks after receiving oral tablets of either vilazodone (20-40mg/d), escitalopram (10-20mg/d), or vortioxetine (5-20mg/d). This study is CTRI-registered (2022/07/043808). Results: Of 71 recruited participants, 49 (69%) completed the 12-week visit. The median Hamilton Depression Rating Scale (HDRS) scores of the participants in vilazodone, escitalopram, and vortioxetine groups were 30.0, 29.5, and 29.0 at baseline (p=0.76) and 19.5, 19.5, and 18.0 (p=0.18) at 12 weeks, respectively. The median fasting blood sugar (FBS) values were 98.5, 105.5, and 98.0 at baseline (p=0.07) and 94.0, 99.5, and 96.0 (p=0.19) at 12 weeks, for vilazodone, escitalopram, and vortioxetine groups, respectively. The post hoc analysis did not yield statistically significant differences regarding any parameters. Conclusion: According to this interim study, the HDRS scores declined after 12 weeks of therapy. The subjects' metabolic parameters did not significantly change. It is essential to perform further investigation regarding these impacts.
Delivery and immigration: the experience of an Italian hospital.

N. Rizzo,V. Ciardelli,G. Gandolfi Colleoni,B. Bonavita,Chiara Parisio,A. Farina,L. Bovicelli

DOI: https://doi.org/10.1016/J.EJOGRB.2004.02.018

2004-10-15

Abstract:
A 3-Month Prospective Real-Life Study

Angel L. Montejo,Froilán Sánchez-Sánchez,Rubén De Alarcón,Juan Matías,Benjamin Cortés,Claudia Matos,Tomás Martín-Pinto,Peñitas Ríos,Nerea González-García,José María Acosta

DOI: https://doi.org/10.3390/jcm13020546

IF: 3.9

2024-01-19

Journal of Clinical Medicine

Abstract:Treatment-emergent sexual dysfunction (TESD) is one of the most frequent and persistent adverse effects of antidepressant medication. Sexual dysfunction (SD) secondary to SSRIs occurs in >60% of sexually active patients and >80% of healthy volunteers, with this causing treatment discontinuation in >35% of patients. However, this factor is rarely addressed in routine examinations, and only 15–30% of these events are spontaneously reported. A strategy of switching to a different non-serotonergic antidepressant could involve a risk of relapse or clinical worsening due to a lack of serotonergic activity. Vortioxetine appears to have less impact on sexual function due to its multimodal mechanism of action. No studies have been published on the effectiveness of switching to vortioxetine in patients with poorly tolerated long-term antidepressant-related SD in naturalistic settings. Study objectives: To determine the effectiveness of switching to vortioxetine due to SD in a routine clinical practice setting. Methodology: observational pragmatic and naturalistic study to determine the effectiveness of the switch to vortioxetine (mean dosage 13.11 ± 4.03) in 74 patients aged 43.1 ± 12.65 (54% males) at risk of discontinuing treatment due to sexual dysfunction. The PRSexDQ*- SALSEX scale (* Psychotropic-Related Sexual Dysfunction Questionnaire) was applied at two moments: baseline visit and after 3 months of follow-up. Results: global Sexual Dysfunction (SD) measured with the SALSEX scale decreased significantly between the baseline visit (10.32; SD 2.73) and the follow-up visit (3.78; SD 3.68), p < 0.001. There was a significant improvement (p < 0.001) at the endpoint including decreased libido, delay of orgasm, anorgasmia and arousal difficulties in both sexes. After switching to vortioxetine, 83.81% of patients experienced an improvement in sexual function (43.2% felt greatly improved). Most patients (83.3%) who switched to vortioxetine continued treatment after the follow-up visit. A total of 58.1% of patients showed an improvement in depressive symptoms from the baseline visit. Conclusion: switching to vortioxetine is an effective and reliable strategy to treat patients with poorly tolerated previous antidepressant-related sexual dysfunction in real-life clinical settings.

medicine, general & internal
Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults

Xinyan Zhang,Yuchun Cai,Xiaowen Hu,Christine Y. Lu,Xiaoyan Nie,Luwen Shi

DOI: https://doi.org/10.3389/fpsyt.2022.922648

IF: 4.7

2022-01-01

Frontiers in Psychiatry

Abstract:Objective: We aimed to compare the efficacy, acceptability, and tolerability of vortioxetine in the treatment of Major Depressive Disorder (MDD) in adults. Method: We searched PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Clinical Trials (CENTRAL), and for randomized controlled trials that examined vortioxetine vs. placebo or other antidepressants for the treatment of MDD from database inception to August 30, 2021, using keywords Vortioxetine, Brintellix, Trintellix, LuAA21004, major depressive disorder, mood disorder, affective disorder, and MDD. We identified 789 publications after removing duplicates. After screening, 20 eligible randomized controlled trials were identified, of which 19 were included in the final meta-analysis. We included adults (aged 18 years and older) with a primary diagnosis of MDD. Two review authors independently selected the studies and extracted data. We extracted data on study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy, acceptability, and tolerability. Analyses were performed using random-effects models, and outcomes were pooled as risk ratios (RRs) and standardized mean differences (SMDs). Results: In total, 20 studies (8,547 participants) met the inclusion criteria. Vortioxetine outperformed the placebo in efficacy outcomes, including response (RR 1.35, 95% CI 1.23-1.48; P < 0.001), remission (RR 1.33, 95% CI 1.17-1.52; P < 0.001), and cognitive function (SMD 0.34, 95% CI 0.16-0.52; P = 0.0003). Compared with the serotonin noradrenaline reuptake inhibitors (SNRIs), vortioxetine had better tolerability (RR 0.90, 95% CI 0.86-0.94; P < 0.001) but no significant difference in response (RR 0.91, 95%CI 0.82-1.00; P = 0.06) or remission (RR: 0.99, 95% CI 0.81-1.20, P = 0.88). Vortioxetine had no difference in response (RR 1.08, 95% CI 0.88-1.32; P = 0.46), remission (RR 1.00, 95% CI 0.41-2.44; P = 1.00) comparing with selective serotonin reuptake inhibitors (SSRIs). Conclusions: Vortioxetine is more advantageous over placebo in treating MDD among adults, but no significant difference compared to SNRIs and SSRIs in general.Systematic Review Registration, identifier: CRD42021278355.
[Stimulation of pulmonary tumorigenesis by urethane in BALB/c mice pretreated with soluble antigens extracted from a mammary tumor in ascitic form (ATPC+) by use of hypertonic solutions of potassium chloride].

R. Ribacchi

Abstract:

Sleep apnoea-insomnia.

Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study

A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD)

The effectiveness of vortioxetine on neurobiochemical metabolites and cognitive of major depressive disorders patients: A 8-week follow-up study

A 12-Month, Retrospective, Observational Study

Clinicopathologic conference: bluish gingival nodule.

Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232.

The role of community pharmacists in prescribing medication for the treatment of head lice.

How to Construct a Logic for Your Application

Screening and prevention trials step up minority recruitment.

Clinical Benefits, efficacy and tolerability of slowly titrated vortioxetine oral drops solution

Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial

Efficacy of vortioxetine versus desvenlafaxine in the treatment of functional impairment in patients with major depressive disorder: Results from the multinational VIVRE study

Vortioxetine in the Treatment of Major Depressive Disorder Among Working Patients in Routine Clinical Practice: An Analysis of a Post-Marketing Surveillance Study in South Korea

The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence

Effectiveness of Vortioxetine in Working Patients with Major Depressive Disorder in China: A Subgroup Analysis of the RELIEVE China Study

Metabolic Effects of Antidepressants: Results of a Randomized Study's Interim Analysis

Delivery and immigration: the experience of an Italian hospital.

A 3-Month Prospective Real-Life Study

Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults

[Stimulation of pulmonary tumorigenesis by urethane in BALB/c mice pretreated with soluble antigens extracted from a mammary tumor in ascitic form (ATPC+) by use of hypertonic solutions of potassium chloride].